Eliglustat, an oral substrate reduction therapy, is a first-line treatment for adults with Gaucher disease type 1 (GD1) who are poor, intermediate, or extensive CYP2D6 metabolizers (>90% of patients). In the primary analysis of the Phase 3 ENGAGE trial (NCT00891202), eliglustat treatment for 9 months resulted in significant reductions in spleen and liver volumes and increases in hemoglobin concentration and platelet count compared with placebo. We report 18-month outcomes of patients who entered the trial extension period, in which all patients received eliglustat. Of 40 trial patients, 39 entered the extension period, and 38 completed 18 months. Absolute values and percent change over time were determined for spleen and liver volume, hemoglobin concentration, platelet count, bone mineral density, bone marrow burden, and Gaucher disease biomarkers. For patients randomized to eliglustat in the double-blind period, continuing treatment with eliglustat for 9 more months resulted in incremental improvement of all disease parameters.
| I N TR ODU C TI ON
Gaucher disease type 1 (GD1) is an autosomal recessive lysosomal storage disorder caused by GBA mutations and defective acid-b-glucosidase. 1 The metabolic defect results in progressive accumulation of glucosylceramide and glucosylsphingosine in lysosomes, most conspicuously in the cells of macrophage/monocyte lineage. The accumulating lipids trigger metabolic inflammation and immune activation that is associated with increased synthesis of glucosylceramide via induction of glucosylceramide synthase, thus amplifying the primary metabolic defect 2, 3 ; hence, the typical phenotypic features of hepatosplenomegaly, cytopenia, and disabling skeletal complications. 1 Two treatment approaches have been used to lower pathological glucosylceramide accumulation in Gaucher disease. For the past two decades, the standard of care for GD1 has been enzyme replacement therapy (ERT)
with biweekly infusions of macrophage-targeted recombinant acid b-glucosidase, which supplements enzyme activity in the macrophage system. 4 Substrate reduction therapy is predicated on partial inhibition of glucosylceramide synthase to decrease synthesis of glucosylceramide to balance residual activity of mutant acid b-glucosidase. 4 Eliglustat (Cerdelga, Sanofi Genzyme, Cambridge, Massachusetts)
is an oral substrate reduction therapy approved as a first-line treatment for adults with GD1 whose predicted CYP2D6 metabolizer status, as detected by an FDA-cleared test, is poor, intermediate, or extensive 5 (>90% of patients 6 ). The Phase 3 ENGAGE trial (NCT00891202), the first placebo-controlled trial ever conducted in Gaucher disease, demonstrated significant reductions in spleen and liver volumes and increases in hemoglobin concentration and platelet count after 9 months of treatment in eliglustat-treated GD1 patients, while placebotreated patients demonstrated slight worsening of these indicators of disease activity. 7 On completing the 9-month primary analysis period, all patients had the opportunity to continue in the open-label ENGAGE trial extension, in which all patients received eliglustat. We report the 18-month outcomes of the patients who entered the trial extension.
| M E TH ODS
Clinical assessments in the ENGAGE trial were performed as described previously. 7 For eliglustat patients continuing on eliglustat and placebo patients who switched to eliglustat, absolute values and percent change over time were determined for spleen volume, liver volume, hemoglobin concentration, platelet count, bone mineral density, and bone marrow burden score. In addition, plasma levels of the acid b-glucosidase substrates, glucosylceramide and glucosylsphingosine, were measured. Biomarkers of Gaucher disease, serum chitotriosidase and plasma macrophage inflammatory protein 1b (MIP-1b), were also monitored. Moreover, we measured plasma levels of several sphingolipids to assess whether inhibition of glucosylceramide led to diversion of substrates through alternate pathways, namely, GM3 ganglioside, sphingomyelin, and ceramide. Safety data were collected as described previously 7 and assessed with regard to treatment group at baseline and duration of eliglustat treatment. Frequency of adverse events, serious adverse events, and severe adverse events are reported for all eliglustat-treated patients in the trial extension period and presented alongside data for the placebo-treated patients during their time in the 9-month primary analysis period.
| R ESU L TS
Baseline patient characteristics for the ENGAGE population were reported previously.
( Figure 2 ), with similar reductions among placebo-crossover patients. In addition, patients randomized to eliglustat in the double-blind period showed consistent further reductions in these biomarkers during the 9-month extension period. Plasma sphingomyelin and ceramide, which were both in the normal range at baseline, remained well within the normal range (Figure 2 , legend). Overall, patients who were treated with eliglustat for 18 months showed continued improvements in visceral, hematologic, bone, and biochemical parameters after their first 9 months on therapy.
The adverse event profile during the first 9 months of the extension trial was consistent with that reported during the primary analysis period (Table 1 ). There were no withdrawals due to adverse events and no deaths. During eliglustat treatment, 99% of adverse events were classified as mild or moderate. The two adverse events classified as severe were migraine (after 382 days on eliglustat) considered unlikely to be related to eliglustat and arthralgia (after 351 days on eliglustat)
considered not related to eliglustat treatment as arthralgia is common in Gaucher disease. Adverse events reported in 15% of patients in any 9-month period are shown in Table 2 .
During eliglustat treatment, 76% of adverse events were considered unrelated to eliglustat and all related adverse events were mild or moderate. The most common related adverse events, each reported in 2-3 patients (5.0%-7.5%) were: headache, diarrhea, nausea, abdominal distension, flatulence, abdominal pain, atrioventricular (AV) block second degree, dizziness, dyspepsia, and dry mouth (Table 3) . Headache, diarrhea, abdominal distension, and abdominal pain were also reported as related events in 3, 4, 1, and 1 placebo-treated patients, respectively, during the 9-month primary analysis period.
In 1 patient, two serious adverse events were reported (AV block and Mobitz type 1 second-degree AV block) during the extension period in protocol-driven Holter monitoring. These two events were observed on a single Holter recording after 421 days on eliglustat.
The patient was asymptomatic but per protocol was hospitalized for evaluation, hence triggering the classification as serious. Both events resolved without treatment, did not lead to study discontinuation, and were considered probably related to eliglustat by the investigator. The patient's dosage was lowered from 150 mg twice daily to 50 mg twice daily, and increased to 100 mg twice daily 4 weeks later.
The external cardiac reviewer concluded that both episodes, which occurred in the early morning hours, were normal physiologic phenomena in a young individual related to nocturnal enhancement of vagal tone.
| D I SCUSSION
The ENGAGE clinical trial was the first randomized placebo-controlled trial in GD1 and met its primary and all secondary endpoints: clinically meaningful and statistically significant improvements in hematologic Absolute mean values for patients initially randomized to placebo or eliglustat are depicted with reference to when they began eliglustat treatment rather than time in the trial. Change from baseline in the table insets is determined with respect to treatment baseline. For patients who received placebo for the first 9 months of the trial, the placebo baseline is when they entered the trial and the eliglustat baseline is when they switched to eliglustat. For patients randomized to eliglustat for the first 9 months, the treatment baseline is when they entered the trial. Abbreviations: MN, multiples of normal; SEM, standard error of the mean and visceral indicators of disease activity were observed in eliglustattreated patients compared with placebo-treated patients during the double-blind, primary analysis period. 7 Recently, eliglustat was approved as a first-line therapy for treatment of adults based on predicted CYP2D6 metabolizer status. Herein, we report the efficacy and safety in the first 9 months of the ENGAGE open-label trial extension.
We found that placebo-crossover patients, who had shown no change Median values for patients initially randomized to placebo or eliglustat are depicted with reference to when they began eliglustat treatment rather than time in the trial. Change from baseline in the table insets is determined with respect to treatment baseline. For patients who received placebo for the first 9 months of the trial, the placebo baseline is when they entered the trial and the eliglustat baseline is when they switched to eliglustat. For patients randomized to eliglustat for the first 9 months, the treatment baseline is when they entered the trial. Not shown: median ceramide remained in the normal range (1.8-6.5 mg/mL) from baseline (3.40 mg/L) to 18 months (4.42 mg/L) and median sphingomyelin remained in the normal range (200-703 mg/mL) from baseline (211.00 mg/mL) to 18 months (280.50 mg/mL) 
Atrioventricular block second degree
Dry mouth 0 (0) 2 (2) 2 (2) a Patient experienced "2:1 AV block" which was coded to "Atrioventricular block" but in this table counted as "Atrioventricular block second degree."
inflammation and skeletal involvement in Gaucher disease. 13 Moreover, 
